Well-konwn biotech focusing on molecular glue development
Location: China
Total raised: $40M
Investors 1
| Date | Name | Website |
| - | New Allian... | nac-capita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.05.2026 | - | $40M | CAS Star |
Mentions in press and media 4
| Date | Title | Description |
| 14.05.2026 | Degron Therapeutics: $40 Million Series A Extension Closed To Support Molecular Glue Degrader Clinical Development | Degron Therapeutics announced the closing of a $40 million Series A Extension financing round to support the continued clinical development of its molecular glue degrader pipeline. The financing round was led by LAPAM CAPITAL, with particip... |
| 13.06.2022 | How VC and PE-backed companies are performing on the public markets, in 3 charts | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Happy Monday! Let’s start the week off on a dark note. It’s pretty easy to do these days—just tak... |
| 10.06.2022 | Degron Therapeutics Raises $22M in Series A Financing | Degron Therapeutics, a San Diego, CA and Shanghai, China-based biotechnology company, raised $22M in Series A funding. The round was led by Med-Fine Capital with participation from Dyee Capital, Baidu Venture, NeuX Capital, CO-WIN Ventures ... |
| - | Degron Therapeutics | “Degron” |